WithdrawnNot Applicable

Evaluation of Interaction Between Immunosuppressive Drugs and Protein-bound Uremic Toxins in Renal Transplant Patients

Stopped: no participants enrolled

France0Started 2021-07-06

Plain-language summary

The majority of studies conducted on uremic toxins involve patients before end stage renal failure or dialysis patients. Only a few studies have focused on transplant patients. In addition, the relationship between serum concentrations of uremic toxins and immunosuppressive drug concentrations has never been studied to date. The investigator research hypothesis is that, due to the strong plasma protein binding of calcineurin inhibitors, an interaction with protein-bound uremic toxins could alter drug concentrations that explain difficulties in reaching therapeutic targets.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * renal transplant patient followed at the University Hospital of Amiens and transplanted for over a year * patient treated with a calcineurin inhibitor * patient having a blood test for evaluation of calcineurin inhibitor concentrations by the toxicology pharmacology laboratory of the Amiens-Picardie University Hospital, * patient affiliated with social security. Exclusion Criteria: * patient in phase of acute rejection of the graft, * patient having opposed his participation, * patient under guardianship or curatorship or deprived of public right

What they're measuring

plasma tacrolimus concentration without plasma uremic toxin adjustment

Timeframe: at day 0

plasma tacrolimus concentration with plasma uremic toxin adjustment

Timeframe: at day 0

Trial details

NCT IDNCT04963673

SponsorCentre Hospitalier Universitaire, Amiens

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-09-12

View on ClinicalTrials.gov More Kidney Transplant trials